Early Detection of COVID-19 Using Breath Analysis -Feasibility Study.
An interventional diagnostic prospective study study with risks and minimal constraints.
Diagnostic Test: Breath Biopsy
Breath Biopsy sampling using the ReCIVA® Breath Sampler
Inclusion Criteria:
Hospitalized group:
- Age 18 to 75 years at the time of consent
- Positive results for SARS-CoV-2
- Capable of understanding written and/or spoken language
- Able to provide informed consent
- Was not treated with Anti-viral drugs
- Not a pregnant woman
Healthy group:
- Healthy volunteers
- Age 18 to 75 years at the time of consent
- No history of COVID-19
- Capable of understanding written and/or spoken language
- Able to provide informed consent
- Was not treated with Anti-viral drugs
- Not a pregnant woman
Sexes Eligible for Study: All
Exclusion Criteria:
Hospitalized group:
- Age under 18 years old
- (Anticipated) inability to complete breath sampling procedure due to e.g. hyper- or
hypoventilation, respiratory failure or claustrophobia when wearing the sampling mask
- Persons under guardianship or deprived of liberty
- Patients with the following diseases: Cancer, Asthma, Chronic Respiratory Disease
Healthy group:
- Age under 18 years old
- History of COVID-19
- Persons under guardianship or deprived of liberty
- Subjects with the following diseases: Cancer, Asthma, Chronic Respiratory Disease
Soroka Medical Center
Be'er Sheva, Israel
Meir Medical Center
Kfar Saba, Israel
David Shitrit, MD, Principal Investigator
Meir Medical Center, Kfar Saba, Israel